Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach.
| Autor: | Isaacs, Diana M., Kruger, Davida F., Spollett, Geralyn R. |
|---|---|
| Předmět: |
BODY weight
CARDIOVASCULAR diseases risk factors CLINICAL trials COMMUNICATION COUNSELING DECISION making DIABETES DRUGS DRUG labeling HYPOGLYCEMIA INJECTIONS KIDNEY diseases MEDICAL care ORAL drug administration PATIENT compliance PATIENT education PATIENTS PHARMACEUTICAL chemistry QUALITY of life SELF-management (Psychology) DRUG development OCCUPATIONAL roles TREATMENT effectiveness GLUCAGON-like peptide-1 agonists GLYCEMIC control PHARMACODYNAMICS |
| Zdroj: | Diabetes Spectrum; Winter2021, Vol. 34 Issue 1, p7-19, 13p |
| Abstrakt: | In September 2019, the U.S. Food and Drug Administration approved oral semaglutide as the first orally administered glucagon-like peptide 1 (GLP-1) receptor agonist for treating people with type 2 diabetes. Although injectable GLP-1 receptor agonists are well-established treatment options for people with type 2 diabetes, clinical experience with an oral formulation in this class is limited. This article provides practical guidance for diabetes care and education specialists on how to effectively counsel patients initiating therapy with oral semaglutide on appropriate administration of the treatment and its possible effects on glycemic control, body weight, and quality of life. Strategies for mitigating potential side effects typical of the GLP-1 receptor agonist class, namely nausea, vomiting, and diarrhea, are also provided. Involving patients in treatment decisions and educating them about available and prescribed medications are key strategies for encouraging treatment adherence and ensuring optimal therapeutic outcomes. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|